| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce3d57a6fc2fad533ce367f648d280ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00a421ab71bd49a451d0a49d23a082c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8528ff66470c896b6da8ed059464e31f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2013-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0efdf7bfe1d05d0c7a555b9b83013ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37497404a00bb30cf4bda6903ed0798f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea9b47eb95f247750582922934b1ff63 |
| publicationDate |
2013-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2013121042-A1 |
| titleOfInvention |
PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER |
| abstract |
The present application relates to the field of cancer treatment. In a first aspect, it particularly relates to treatment of cancers by using the concept of synthetic lethality. It is shown that suppression or loss of function of particular subunits of the heterotrimeric serine/threonine phosphatases 2A (PP2A) sensitizes cells to inhibition of DNA base excision repair, such as e.g. PARP inhibition. These findings can be used to screen for patients sensitive to therapies based on DNA base excision repair inhibition, as well as used therapeutically by administering inhibitors of PP2A subunits, particular in combination with inhibitors of DNA base excision repair, such as PARP inhibitors. Interestingly, it is also shown that a particular PP2A subunit, B55α, is a novel interacting protein of the oxygen sensor PHD2. Both proteins are negative regulators of each other, and it is shown herein that B55α in tumor cells leads to apoptosis of these cells and thus to smaller tumors. Thus, inhibitors of the PP2A B55α subunit as such can also be used therapeutically in the treatment of cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2774160-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11597934-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9944931-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10876120-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015153838-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016526883-A |
| priorityDate |
2012-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |